Once-Weekly Semaglutide in Adults with Overweight or Obesity.
暂无分享,去创建一个
T. Wadden | J. Rosenstock | M. Davies | L. V. Van Gaal | R. Kushner | R. Batterham | K. Yokote | J. Wilding | S. Calanna | I. Lingvay | S. Wharton | B. McGowan | Marie T D Tran | N. Zeuthen
[1] D. Skovgaard,et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity , 2020, Diabetes, obesity & metabolism.
[2] M. Gagner,et al. Obesity in adults: a clinical practice guideline , 2020, Canadian Medical Association Journal.
[3] Chunyan Zhu,et al. Obesity aggravates COVID‐19: A systematic review and meta‐analysis , 2020, Journal of medical virology.
[4] T. Wadden,et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 , 2020, Obesity.
[5] G. Lippi,et al. Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide , 2020, Mayo Clinic Proceedings.
[6] J. Ahnfelt-Rønne,et al. Semaglutide lowers body weight in rodents via distributed neural pathways. , 2020, JCI insight.
[7] C. L. le Roux,et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial , 2020, Diabetologia.
[8] 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.
[9] M. Nauck,et al. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonist equal in the treatment of type 2 diabetes? , 2019, European journal of endocrinology.
[10] M. Davies,et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. , 2019, Diabetes & metabolism.
[11] J. Buse,et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial , 2019, Diabetes Care.
[12] K. Lyseng-Williamson. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features , 2019, Clinical Drug Investigation.
[13] L. B. Knudsen,et al. The Discovery and Development of Liraglutide and Semaglutide , 2019, Front. Endocrinol..
[14] P. O'Neil,et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial , 2018, The Lancet.
[15] J. Després,et al. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. , 2018, Circulation.
[16] D. Bessesen,et al. Progress and challenges in anti-obesity pharmacotherapy. , 2017, The lancet. Diabetes & endocrinology.
[17] R. Kolotkin,et al. A systematic review of reviews: exploring the relationship between obesity, weight loss and health‐related quality of life , 2017, Clinical obesity.
[18] G. Finlayson,et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity , 2017, Diabetes, obesity & metabolism.
[19] M. Kahle,et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials , 2017, Diabetes, obesity & metabolism.
[20] 2. Classification and Diagnosis of Diabetes , 2016, Diabetes Care.
[21] E. Livingston,et al. Bariatric Surgery and Long-term Durability of Weight Loss. , 2016, JAMA surgery.
[22] A. Barkun,et al. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. , 2016, JAMA internal medicine.
[23] R. Plodkowski,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[24] L. de las Fuentes,et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. , 2016, Cell metabolism.
[25] Luca Busetto,et al. European Guidelines for Obesity Management in Adults , 2015, Obesity Facts.
[26] D. Williamson,et al. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? , 2015, Obesity.
[27] A. Astrup,et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.
[28] Deepak L. Bhatt,et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. , 2014, The New England journal of medicine.
[29] Luis Garcia,et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. , 2013, JAMA.
[30] L. Sjöström. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery , 2013, Journal of internal medicine.
[31] Colin D Johnson,et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus , 2012, Gut.
[32] S. Litwin,et al. Reductions in cardiovascular risk after bariatric surgery , 2011, Current opinion in cardiology.
[33] A. Shulkes,et al. Long-term persistence of hormonal adaptations to weight loss. , 2011, The New England journal of medicine.
[34] T. Wadden,et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes , 2011, Diabetes Care.
[35] C. Canullán,et al. Management of gallstones and gallbladder disease in patients undergoing gastric bypass. , 2010, World journal of gastroenterology.
[36] R. Collins,et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, The Lancet.
[37] Wei Zhang,et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis , 2009, BMC public health.
[38] S. Erlinger. Gallstones in obesity and weight loss. , 2000, European journal of gastroenterology & hepatology.